Company news

Protara Therapeutics, Inc. news in 2025

Protara Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Protara Announces Closing of $75 Million Public Offering

December 8, 2025

Protara Announces Pricing of $75 Million Public Offering

December 4, 2025

Protara Announces Proposed Public Offering

December 4, 2025

Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients

December 3, 2025

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025

December 1, 2025

Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

November 19, 2025

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025

November 18, 2025

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology

November 17, 2025

Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

November 10, 2025

Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace

November 4, 2025

Protara Therapeutics to Participate in Upcoming Investor Conferences

August 27, 2025

Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

August 11, 2025

Protara Therapeutics Announces Addition to the Russell 3000® Index

June 30, 2025

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

June 2, 2025

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

April 26, 2025

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

April 23, 2025

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

April 15, 2025

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

April 10, 2025

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

March 19, 2025

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

March 5, 2025

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

February 26, 2025

Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 4, 2025

Protara Highlights Recent Updates and Anticipated 2025 Milestones

January 12, 2025

Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7, 2025

Decks in 2025